Immune Enhancing Articles & Analysis: Older
14 news found
In fact, ExcellGene demonstrated that a single 40 L bioreactor based production run can provide antigens in sufficient quantity to immunize about 5 million people, i.e. half of the Swiss population. Most promising data were shared on an ExcellGene patented principle for generating chimaeric antigens. ...
Cancer Vaccine Development Based on pMHC Cancer vaccines to enhance the immune response, target tumor-specific mutations not present in normal tissues, and eradicate tumors. ...
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a ...
Airfinity predicts a potential ‘twindemic’ of COVID-19 and flu could overwhelm hospitals this winter. The analysis focuses on two potential scenarios, based on data from previous winter COVID-19 waves driven by the Alpha and Omicron BA.1 variants as well as historical flu admissions from 2017-2018, the last bad flu season, as another bad flu season is expected this year based on ...
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. ...
ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree. ImmunAdd is undertaking the development of IA-05 in collaboration with several biopharma ...
Cipla also recently launched a biosimilar for the treatment of immune-mediated inflammatory disease. According to the Cancer Alliance report CA03/2021, South Africa faces a crisis in terms of affordable access to medicines, particularly in the treatment of cancer. ...
” Tweet this “To our knowledge, this is the first randomized clinical trial to demonstrate that a live bacterial product can modulate the gastrointestinal microbiome and enhance immunotherapy response in cancer patients. These results can help improve treatment options for patients with kidney cancer and is an important foundational step to bring about more ...
To help achieve its long-term growth strategy, the Company's strategic priorities for 2022 include: Maximize Growth of HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recently upgraded recommendations from the CDC's Advisory Committee on Immunization Practices advise that all adults aged 19-59 be vaccinated against Hepatitis-B, creating a significantly expanded ...
PseudoUridine PseudoUridine has a subtle but significant effect on the nearby sugar phosphate backbone and enhances base accumulation. It is considered to be a regulator of the latent process of the human immunodeficiency virus (HIV) infection. ...
“There is considerable interest in microbiome modulation to enhance immune checkpoint inhibitor efficacy that is more consistent and scalable than fecal transplants. ...
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the exclusive right to use MV Bio ...
Leveraging Gut Microbiota Cross-Talk with Immune System to Enhance Cancer Immunotherapy Extracellular ATP (eATP) as a bacterial metabolite in host-microbiota mutualism Adaptive modulation of intestinal immunity by inhibition of eATP signalling Enhancement of immune checkpoint blockade by eATP interfering ...
MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies. “We weren’t sure about the potential success when we applied to the Swiss Pavillon with the sponsoring of Innosuisse” confirms Dr. Fabio Grassi, founder and chairman. “The support we got from Switzerland Global ...